Analysis of different deleted regions in chromosome 11 and their interrelations in early- and late-onset breast tumors: Association with Cyclin D1 amplification and survival

Diagnostic Molecular Pathology

Volumn 13, Issue 3, 2004, Pages 172-182

  Chunder, Neelanjana ^a   Mandal, Syamsundar ^a   Roy, Anup ^b   Roychoudhury, Susanta ^c   Panda, Chinmay Kumar ^a  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^b BANKURA SAMMILANI MEDICAL COLLEGE   (India)

^c INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

Chromosome 11; Cyclin D1; Early onset breast cancer; Late onset breast cancer; LOH

Indexed keywords

CYCLIN D1;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; BREAST TUMOR; CANCER SURVIVAL; CHROMOSOME 11; CHROMOSOME 11P; CHROMOSOME 11Q; CHROMOSOME ABERRATION; CHROMOSOME DELETION; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE LOCUS; GENE MAPPING; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MICROSATELLITE MARKER; ONSET AGE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGE OF ONSET; AGED; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CHROMOSOMES, HUMAN, PAIR 11; FEMALE; GENE AMPLIFICATION; GENES, BCL-1; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 4344583855     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pas.0000124337.49401.0b     Document Type: Article

References (59)

1. Alberg AJ, Lam AP, Helzlsouer KJ. Epidemiology, prevention and early detection of breast cancer. Curr Opin Oncol. 1999;11:435-441.
2. Rao DN, Ganesh B. Estimate of cancer incidence in India in 1991. Indian J Cancer. 1998;35:10-18.
3. Albain KS, Allred DC, Clark GM. Breast cancer outcome and predictors of outcome: Are there age differentials? J Natl Cancer Inst Monogr. 1994;16:35-42.
4. Chung M, Chang HR, Bland KI, et al. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer. 1996;77:97-103.
5. Gentile M, Olsen K, Dufmats M, et al. Frequent allelic losses at 11q24. 1-q25 in young women with breast cancer: Association with poor survival. Br J Cancer. 1999;80:843-849.
6. Gentile M, Wiman A, Thorstenson S, et al. Deletion mapping of chromosome segment 11q24-25, exhibiting extensive allelic loss in early onset breast cancer. Int J Cancer. 2001;92:208-213.
7. Naidu R, Wahab NA, Yadav MM, et al. Expression and amplification of cyclin D1 in primary breast carcinomas: Relationship with histopathological types and clinico-pathological parameters. Oncol Rep. 2002;9:409-416.
8. Maillet P, Bonnefoi H, Vaudan-Vutskits G, et al. Constitutional afterations of the ATM gene in early onset breast cancer. J Med Genet. 2002;39:751-753.
9. Forozan F, Mahlamäki EH, Monni O, et al. Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. Cancer Res. 2000;60:4519-4525.
10. Tirkkonen M, Tanner M, Karhu R, et al. Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer. 1998;21:177-184.
11. Teixiera MR, Pandis N, Heim S. Cytogenetic clues to breast carcinogenesis. Genes Chromosomes Cancer. 2002;33:1-16.
12. Koreth J, Bakkenist CJ, Larin Z, et al. 11q23.1 and 11q25-qter YACs suppress tumor growth in vivo. Oncogene. 1999;18:1157-1164.
13. Negrini M, Sabbioni S, Possati L, et al. Suppression of tumorigenicity of breast cancer cells by microcell mediated chromosome transfer: Studies on chromosomes 6 and 11. Cancer Res. 1994;54:1331-1336.
14. Karnik P, Paris M, Williams BRG, et al. Two distinct tumor suppressor loci within chromosome 11p15 implicated in breast cancer progression and metastasis. Hum Mol Genet. 1998;7:895-903.
15. Winqvist R, Hampton GM, Mannermaa A, et al. Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis. Cancer Res. 1995;55:2660-2664.
16. Washington C, Dalbegue F, Abreo F, et al. Loss of heterozygosity in fibrocystic change of the breast. Am J Pathol. 2000;157:323-329.
17. Nakata T, Yoshimoto M, Kasumi F, et al. Identification of a new commonly deleted region within a 2-cM interval of chromosome 11p11 in breast cancers. Eur J Cancer. 1998;34:417-421.
18. Zhuang Z, Merino MJ, Chuaqui R, et al. Identical allelic loss on chromosome 11q13 in microdissected in situ and invasive human breast cancer. Cancer Res. 1995;55:467-471.
19. Chuaqui RF, Zhuang Z, Emmert-Buck MR, et al. Analysis of loss of heterozygosity on 11q13 in atypical ductal hyperplasia and in situ carcinoma of the breast. Am J Pathol. 1997;150:297-303.
20. Gudmundsson J, Barkardottir RB, Eiriksdottir G, et al. Loss of heterozygosity at chromosome 11 in breast cancer: association of prognostic factors with genetic alterations. Br J Cancer. 1995;72:696-701.
21. Kerangueven F, Eisinger F, Noguchi T, et al. Loss of heterozygosity in human breast carcinomas in the ataxia telangiectasia, Cowden disease and BRCA1 gene regions. Oncogene. 1997;14:339-347.
22. Koreth J, Bakkenist CJ, McGee JOD. Allelic deletions at chromosome 11q22-q23.1 and 11q25-qterm are frequent in sporadic breast but not colorectal cancers. Oncogene. 1997;14:431-437.
23. Negrini M, Rasio D, Hampton GM, et al. Definition and refinement of chromosome 11 regions of loss of heterozygosity in breast cancer: identification of a new region at 11q23.3. Cancer Res. 1995;55:3003-3007.
24. di Iasio MG, Calin G, Tibiletti MG, et al. Refinement of the LOH region 1 at 11q23.1 deleted in human breast carcinomas and sublocalization of 11 expressed sequence tags within the refined region. Oncogene. 1999;18:1635-1638.
25. Monaco C, Negrini M, Sozzi G, et al. Molecular cloning and characterization of LOH11CR2A, a new gene within a refined minimal region of LOH at 11q23. Genomics. 1997;46:217-222.
26. Nathanson KN, Wooster R, Weber BL. Breast cancer genetics: What we know and what we need. Nature Med. 2001;7:552-556.
27. Lindblom A, Sandelin K, Iselius L, et al. Predisposition for breast cancer in carriers of constitutional translocation 11q;22q. Am J Hum Genet. 1994;54:871-876.
28. Swift M, Reitnauer PJ, Morrell D, et al. Breast and other cancers in families with ataxia telangiectasia. N Engl J Med. 1987;316:1289-1294.
29. Laake K, Launonen V, Niederacher D, et al. Loss of heterozygosity at 11q23.1 and survival in breast cancer: results of a large European study. Genes Chromosomes Cancer. 1999;25:212-221.
30. Laake K, Odegard A, Andersen TI, et al. Loss of heterozygosity at 11q23.1 in breast carcinomas: indication for involvement of a gene distal and close to ATM. Genes Chromosomes Cancer. 1997;18:175-180.
31. Vos CBJ, Ter Haar NT, Peterse JL, et al. Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast. J Pathol. 1999;187:279-284.
32. Schuuring E. The involvement of chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes - a review. Gene. 1995;159:83-96.
33. Vaziri SAJ, Tubbs RR, Darlington G, et al. Absence of CCND1 gene amplification in breast tumors of BRCA1 mutation carriers. Mol Pathol. 2001;54:259-263.
34. Chunder N, Mandal S, Basu D, et al. Deletion mapping of chromosome 1 in early onset and late onset breast tumors - A comparative study in eastern India. Pathol Res Pract. 2003;199:313-321.
35. rd ed. Geneva, 1978;47-54.
36. Pandey M, Singh SP, Behere PB, et al. Quality of life in patients with early and advanced carcinoma of the breast. Eur J Surg Oncol. 2000;26:20-24.
37. nd ed. Cold Spring Harbor, NY; Cold Spring Harbor Laboratory, 1989.
38. Dib C, Faure S, Fizames C, et al. A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature. 1996;380: iii-A138.
39. The genome browser gateway [http://genome.ucsc.edu/cgibin/hgGateway].
40. The Genome Database [http://www.gdb.org].
41. Tripathi A, Banerjee S, Chunder N, et al. Differential alterations of the genes in the CDKN2A-CCND1-CDK4-RB1 pathway are associated with the development of head and neck squamous cell carcinoma in Indian patients. J Cancer Res Clin Oncol. 2003;129:642-650.
42. Epi Info [computer program]. Version 6.04b. Atlanta, GA: Centers for Disease Control and Prevention; 1997.
43. Nair MK, Sankaranarayanan R, Nair KS, et al. Overall survival from breast cancer in Kerala, India, in relation to menstrual reproductive and clinical factors. Cancer. 1993;71:1791-1796.
44. Sellar GC, Watt KP, Rabiasz GJ, et al. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nature Genet. 2003;34:337-343.
45. Martin ES, Cesari R, Pentimalli F, et al. The BCSC-1 locus at chromosome 11q23-q24 is a candidate tumor suppressor gene. Proc Natl Acad Sci U S A. 2003;100:11517-11522.
46. Oda K, Arakawa H, Tanaka T, et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell. 2000;102:849-862.
47. Gentile M, Ahnstrom M, Schon F, et al. Candidate tumor suppressor genes at 11q23-24 in breast cancer: evidence of alterations in PIG8, a gene involved in p53-induced apoptosis. Oncogene. 2001;20:7753-7760.
48. Wang SS, Esplin ED, Li JL, et al. Alterations of the PPP2R1B gene in human lung and colon cancer. Science. 1998;282:284-287.
49. Srivatsan ES, Chakrabarti R, Zainabadi K, et al. Localization of deletion to a 300 Kb interval of chromosome 11q13 in cervical cancer. Oncogene. 2002;21:5631-5642.
50. Huang X, Gollin SM, Raja S, et al. High resolution mapping of the 11q13 amplicon and identification of a gene, TAOS1, that is amplified and overexpressed in oral cancer cells. Proc Natl Acad Sci U S A. 2002;99:11369-11374.
51. Ruivenkamp CAL, van Wezel T, Zanon C, et al. PTPRJ is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. Nature Genet. 2002;31:295-300.
52. Yang X, Wei LL, Tang C, et al. Overexpression of KAI1 suppresses in vitro invasiveness and in vivo metastasis in breast cancer cells. Cancer Res. 2001;61:5284-5288.
53. Hu RJ, Lee MP, Connors TD, et al. A 2.5-Mb transcript map of a tumor-suppressing subchromosomal transferable fragment from 11p15.5, and isolation and sequence analysis of three novel genes. Genomics. 1997;46:9-17.
54. van Roozendaal CEP, Gillis AJM, Klijn JGM, et al. Loss of imprinting of IGF2 and not H19 in breast cancer, adjacent normal tissue and derived fibroblast cultures. FEBS Lett. 1998;437:107-111.
55. Wang Q, Driouch K, Courtois S, et al. Low frequency of TSG101/CC2 gene alterations in invasive human breast cancers. Oncogene. 1998;16:677-679.
56. Arai Y, Hosoda F, Kobayashi H, et al. The inv(11)(p15q22) chromosome translocation of de novo and therapy-related myeloid malignancies results in fusion of nucleoporin gene, NUP98, with the putative RNA helicase gene, DDX10. Blood. 1997;89:3936-3944.
57. Perucca-Lostanlen D, Hecht BK, Courseaux A, et al. Mapping FRA11A, a folate sensitive fragile site in human chromosome band 11q13.3. Cytogenet Cell Genet. 1997;79:88-91.
58. Saunders WS, Shuster M, Huang X, et al. Chromosomal instability and cytoskeletal defects in oral cancer cells. Proc Natl Acad Sci U S A. 2000;97:303-308.
59. Jin Y, Hoglund M, Jin C, et al. Fish characterization of head and neck carcinomas reveals that amplification of band 11q13 is associated with deletion of distal 11q. Genes Chromosomes Cancer. 1998;22:312-320.